Predictive value of 99mTc sestamibi scintigraphy in the evaluation of doxorubicin based chemotherapy response in patients with advanced breast cancer

Nuclear Medicine Communications

Volumn 23, Issue 8, 2002, Pages 765-771

  Alonso, O ^a   Delgado, L ^a   Nunez M ^a   Vargas, C ^a   Lopera, J ^a   Andruskevicius, P ^a   Sabini, G ^a   Gaudiano, J ^a   Muse I M ^a   Roca, R ^a  

^a UNIVERSITY OF URUGUAY   (Uruguay)

Author keywords

99mTc MIBI; Advanced breast cancer; Chemotherapy response; Scintimammography

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN; ANTINEOPLASTIC AGENT; CAF PROTOCOL; CYCLOPHOSPHAMIDE; DIAGNOSTIC AGENT; FLUOROURACIL; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CHEMOTHERAPY; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIDRUG RESISTANCE; PREDICTION; PROTEIN EXPRESSION; SCINTIMAMMOGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMAN; MIDDLE AGE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SUPPORT, NON-U.S. GOV'T; TECHNETIUM TC 99M SESTAMIBI; HUMANS; MIDDLE AGED;

EID: 0035991807     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200208000-00010     Document Type: Article

References (34)

1. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
2. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000; 18: 724-733.
3. Esteva F, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi N. Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond. The Oncologist 2001; 6: 133-146.
4. Kroger N, Achterrath W, Hergewisch-Becker S, Mross K, Zander AR. Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev 1999; 25: 279-291.
5. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000; 12: 450-458.
6. Linn SC, Pinedo HM, van Ark-Otte J, et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 1997; 71: 787-795.
7. Ito K, Fujimori M, Nakata S, et al. Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer. Oncol Res 1998; 10: 99-109.
8. Linn SC, Giaccone G, van Diest PJ, et al. Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol 1995; 6: 679-685.
9. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89: 917-931.
10. Chung HC, Rha SY, Kim JH, et al. P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 1997; 42: 65-72.
11. Gianni L. Anthracycline resistance: the problem and its current definition. Semin Oncol 1997; 24(Suppl. 10): S10-S17.
12. Palmedo H, Biersack HJ, Lastoria S, et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med 1998; 25: 375-385.
13. 99mTc sestamibi breast imaging: Multicenter trial results. J Nucl Med 2000; 41: 1973-1979.
14. 99mTc-sestamibi scintimammography complementary to conventional mammography for detecting breast cancer patients with palpable masses? J Nucl Med 2001; 42: 1614-1621.
15. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutylisonitrile) technetium (I): mitochondrial and plasma membrane potential dependence. Circulation 1990; 82: 1823-1838.
16. Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
17. Crankshaw C, Piwnica-Worms D. Tc-99m-sestamibi may be a transport substrate of the human multidrug resistance-associated protein (MRP). J Nucl Med 1996; 37: 247.
18. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein (MRP). Br J Cancer 1998; 77: 353-358.
19. 99mTc tetrofosmin. Biochem Pharm 2000; 60: 413-426.
20. Kostakoglu L, Kirath P, Ruacan S, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 1998; 39: 228-234.
21. Taki J, Sumiya H, Asada N, Ueda Y, Tsuchiya H, Tonami N. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. J Nucl Med 1998; 39: 1179-1184.
22. 99mTc-MIBI uptake and P-glycoprotein expression in tumor tissue. Eur J Nucl Med 1996; 23: 976-979.
23. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Lee JK, Kao CH. Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results. Cancer Letters 2000; 153: 95-100.
24. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Lee JK, Kao CH. Expression of drug resistance protein related to Tc-99m MIBI breast imaging. Anticancer Res 2000; 30: 2021-2026.
25. Kao CH, Tsai SC, Liu TJ, et al. P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. Cancer Res 2001; 15: 1412-1414.
26. Vecchio SD, Ciarmiello A, Potena MI, et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997; 24: 150-159.
27. 99mTc-MIBI scintigraphy as an indicator of the chemosensitivity of anthracyclines in patients with breast cancer. Anticancer Res 1998; 18: 4601-4606.
28. Pace L, Catalano L, Del Vecchio S, et al. Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up. Eur J Nucl Med 2001; 28: 304-312.
29. Nishiyama Y, Yamamoto Y, Satoh K, et al. Comparative study of Tc-99m MIBI and Tl-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer. Clin Nucl Med 2000; 25: 364-369.
30. Ciarmiello A, Del Vecchio S, Silvestro P, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998; 16: 1677-1683.
31. Takamura Y, Miyoshi Y, Taguchi T, Noguchi S. Prediction of chemotherapeutic response by technetium 99m-MIBI scintigraphy in breast carcinoma patients. Cancer 2001; 92: 232-239.
32. Cwikla JB, Buscombe JR, Barlow RW, et al. The effect of chemotherapy on the uptake of technetium-99m sestamibi in breast cancer. Eur J Nucl Med 1997; 24: 1174-1179.
33. Geworski L, Knoop BO, Levi de Cabrejas M, Knapp WH, Munz DL. Recovery correction for quantitation in emission tomography: a feasibility study. Eur J Nucl Med 2000; 27: 161-169.
34. Schneider J, Gonzalez-Roces S, Pollán M, et al. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res 2001; 3: 183-191.